Published in Obesity and Diabetes Week, June 6th, 2005
For the 3 months ended March 31, 2005, the net loss applicable to common stockholders was $1,293,000, or $.06 per share, as compared to $1,403,000, or $.11 per share, for the same period in 2004.
The company ended the quarter with $7,892,000 in cash and short term investments. The company expects that its cash and short term investments on hand will be sufficient to fund operations through at least June, 2006.
Among the highlights reported for the first quarter, is that SonoPrep and the procedure tray for topical lidocaine...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week